Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Avelumab + PF-04518600 + Utomilumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Avelumab||Bavencio||MSB0010718C||Immune Checkpoint Inhibitor 154 PD-L1/PD-1 antibody 106||Bavencio (avelumab) is a monoclonal antibody binds to human immunosuppressive ligand programmed death-ligand 1 (PD-L1, CD274) and blocks protein signaling, resulting in immune regulation and antitumor immunity (PMID: 26014098). Bavencio (avelumab) is FDA-approved for use in adult and pediatric patients of 12 years or older with metastatic Merkel cell carcinoma, as maintenance therapy in locally advanced or metastatic urothelial carcinoma (UC), in locally advanced or metastatic UC that progressed following chemotherapy, and in combination with axitinib as first-line therapy in advanced renal cell carcinoma (FDA.gov).|
|PF-04518600||PF-8600|PF04518600|Ivuxolimab||OX40 Antibody 13||PF-04518600 (Ivuxolimab) is an activating monoclonal antibody to TNFRSF4 (OX40, CD134), which mimics the binding of the ligand, TNFSF4 (OX40L, CD252), to stimulate proliferation of T-cells and enhance an anti-tumor response (Journal of Clinical Oncology 34, no. 15_suppl (May 20 2016) 3079-3079).|
|Utomilumab||PF-05082566|PF05082566||TNFRSF9 Antibody 24||Utomilumab (PF-05082566) is an activating monoclonal antibody that targets and antagonizes CD137 (4-1BB), potentially resulting in increased immune response against tumor cells (PMID: 27369047, PMID: 32144134).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02554812||Phase Ib/II||Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab||A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)||Terminated||USA | GBR | FRA | CAN | AUS||3|
|NCT03217747||Phase Ib/II||Avelumab + PF-04518600 + Utomilumab Avelumab + Utomilumab Avelumab + PF-04518600||Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies||Active, not recruiting||USA||0|